We report here that Poloppin and Poloppin-II, compounds that target the protein-protein interactions of human Polo-like kinases, suppress the growth of KRAS-mutant cancer cells as single agents, or in combination with c-MET inhibitors. The gene discussed is KRAS; the disease is cancer.